Central administration of corticotropin-releasing factor modulates oxytocin secretion in the rat.

Bruhn TO, Sutton SW, Plotsky PM, Vale WW

Endocrinology1 Oct 1986Cited by 63 (Europe PMC)

PMID3019636DOI10.1210/endo-119-4-1558PepBankPUB-03019636

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Natural levels measured7

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01AnimalEndogenous levelAnimal study (in vivo)Other
In male rats, intracerebroventricular CRF raised the body's own oxytocin secretion 3.4-fold.
In plain wordsIn male rats, CRF injected into the brain raised the body's own oxytocin release about 3.4 times.
Peptide
Oxytocin
Outcome
IncreaseOT secretion after icv CRF in male rats
Study
ratn: not reported in source
Rats given CRF; plasma OT measured
Outcome group
Stress hormones · Endocrine and hormones
Measurements
OT secretion fold increase
3.4 fold
male rats, icv CRF
Source sentences
Summary
CRF significantly elevated OT secretion in male and female rats 3.4- and 4-fold, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Male and female rats received intraventricular (icv) injections of 0.75 nmol (5 micrograms) rat CRF and were killed 5 min after the treatment.
This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0301963601
02AnimalEndogenous levelAnimal study (in vivo)Other
In female rats, intracerebroventricular CRF raised the body's own oxytocin secretion 4-fold.
In plain wordsIn female rats, CRF injected into the brain raised the body's own oxytocin release about 4 times.
Peptide
Oxytocin
Outcome
IncreaseOT secretion after icv CRF in female rats
Study
ratn: not reported in source
Rats given CRF; plasma OT measured
Outcome group
Stress hormones · Endocrine and hormones
Measurements
OT secretion fold increase
4 fold
female rats, icv CRF
Source sentences
Summary
CRF significantly elevated OT secretion in male and female rats 3.4- and 4-fold, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Male and female rats received intraventricular (icv) injections of 0.75 nmol (5 micrograms) rat CRF and were killed 5 min after the treatment.
This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0301963602
03AnimalEndogenous levelAnimal study (in vivo)Other
In rats, rat CRF, ovine CRF and sauvagine were equipotent releasers of the body's own oxytocin.
In plain wordsIn rats, three related peptides released the body's own oxytocin to the same extent.
Peptide
Oxytocin
Outcome
IncreaseOT release by rat CRF, ovine CRF and sauvagine
Study
ratn: not reported in source
Rats given CRF; plasma OT measured
Outcome group
Stress hormones · Endocrine and hormones
Source sentences
Summary
The effect of CRF on OT release was structure specific since rat CRF, ovine CRF, and sauvagine were equipotent releasers of OT
1 context sentence(design, population, supporting numbers)
Summary · context
Male and female rats received intraventricular (icv) injections of 0.75 nmol (5 micrograms) rat CRF and were killed 5 min after the treatment.
This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0301963603
04AnimalEndogenous levelAnimal study (in vivo)Other
In rats, an inactive CRF analog did not change plasma levels of the body's own oxytocin.
In plain wordsIn rats, an inactive CRF analog did not change the body's own oxytocin levels in blood.
Peptide
Oxytocin
Outcome
No significant changePlasma OT after inactive CRF analog
Study
ratn: not reported in source
Rats given CRF; plasma OT measured
Outcome group
Stress hormones · Endocrine and hormones
Source sentences
Summary
while an inactive analog to CRF, ovine CRF did not change plasma OT levels
1 context sentence(design, population, supporting numbers)
Summary · context
Male and female rats received intraventricular (icv) injections of 0.75 nmol (5 micrograms) rat CRF and were killed 5 min after the treatment.
This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0301963604
05AnimalEndogenous levelAnimal study (in vivo)Other
In rats, pretreatment with CRF-antiserum did not influence the oxytocin response to intracerebroventricular CRF.
In plain wordsIn rats, blocking CRF with an antiserum did not change the rise in the body's own oxytocin after CRF.
Peptide
Oxytocin
Outcome
No significant changeOT response to icv CRF after CRF-antiserum
Study
ratn: not reported in source
Rats given CRF; plasma OT measured
Outcome group
Stress hormones · Endocrine and hormones
Source sentences
Summary
Both CRF-antiserum and dexamethasone blocked the rise in ACTH release after icv CRF completely but did not influence the OT response.
2 context sentences(design, population, supporting numbers)
Summary · context
In another set of experiments rats were pretreated with either CRF-antiserum (0.5 ml iv) or dexamethasone (20 micrograms/rat ip) and then injected with icv CRF.
Summary · context
Male and female rats received intraventricular (icv) injections of 0.75 nmol (5 micrograms) rat CRF and were killed 5 min after the treatment.
This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0301963605
06AnimalEndogenous levelAnimal study (in vivo)Other
In rats, pretreatment with dexamethasone did not influence the oxytocin response to intracerebroventricular CRF.
In plain wordsIn rats, dexamethasone did not change the rise in the body's own oxytocin after CRF.
Peptide
Oxytocin
Outcome
No significant changeOT response to icv CRF after dexamethasone
Study
ratn: not reported in source
Rats given CRF; plasma OT measured
Outcome group
Stress hormones · Endocrine and hormones
Source sentences
Summary
Both CRF-antiserum and dexamethasone blocked the rise in ACTH release after icv CRF completely but did not influence the OT response.
2 context sentences(design, population, supporting numbers)
Summary · context
In another set of experiments rats were pretreated with either CRF-antiserum (0.5 ml iv) or dexamethasone (20 micrograms/rat ip) and then injected with icv CRF.
Summary · context
Male and female rats received intraventricular (icv) injections of 0.75 nmol (5 micrograms) rat CRF and were killed 5 min after the treatment.
This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0301963606
07AnimalEndogenous levelAnimal study (in vivo)Other
In rats, intravenous CRF increased peripheral blood levels of the body's own oxytocin, with a 2- to 4-fold stimulation similar to that after intracerebroventricular CRF.
In plain wordsIn rats, CRF given into a vein raised the body's own oxytocin in blood about 2 to 4 times.
Peptide
Oxytocin
Outcome
IncreasePlasma OT after intravenous CRF
Study
ratn: not reported in source
Rats given CRF; plasma OT measured
Outcome group
Stress hormones · Endocrine and hormones
Measurements
OT stimulation
2 to 4 fold
intravenous CRF
Source sentences
Summary
Intravenous administration of 0.75 nmol CRF increased both OT and AVP levels in peripheral blood. The magnitude of this increase was similar (2- to 4-fold stimulation) to responses after icv administration of CRF.
This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0301963607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 20:03 UTC
Study results updated
Version 1
9 Oct 2026, 02:54 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.